-
Mashup Score: 12
Timothy Brown, MD, UT Southwestern Medical Center, Dallas, TX, highlights the importance of dialogue between patients and clinicians regarding the side effects and treatment logistics when choosing a second-line treatment for upper gastrointestinal cancer. While ramucirumab with FOLFIRI or paclitaxel are second-line options for patients with minimal neuropathy from first-line treatment, Dr Brown encourages these patients with to opt for FOLFIRI with ramucirumab, which has fewer side effects without reducing second-line survival benefit. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Cisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR. These data establish cisplatin and gemcitabine as a standard approach in gBRCA/PALB2+ PDAC.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Neuroendocrine Tumor-Associated Chromogranin A Tubulopathy - 1 month(s) ago
A 68-year-old male with type 2 diabetes mellitus presented to his primary care physician’s office with worsening bipedal edema, unintentional weight loss, and new-onset serum creatinine elevation at 1.70 mg/dl (normal 0.60- 1.30 mg/dl). A renal ultrasound (US) did not reveal any abnormalities in the kidneys; however, showed multiple masses in the liver. Further evaluation with a computed tomography (CT) scan showed a 12 cm x 6.5 cm x 8 cm pancreatic body and tail mass along with numerous hepatic masses.
Source: www.amjmed.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Novel Therapies for Pancreatic Cancer | JCO Oncology Practice - 2 month(s) ago
Pancreatic adenocarcinoma (PDAC) unfortunately remains a highly fatal disease with a 5-year survival rate of only 11%. If surgical resection is not possible, systemic chemotherapy represents the standard-of-care approach to management. Combination …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24
Purpose: We describe the impact of screening on outcomes of patients diagnosed with hepatocellular carcinoma (HCC) in an urban safety-net healthcare system compared to a non-screened cohort diagnosed with HCC. Methods: Patients diagnosed with HCC at John Peter Smith Health Network were identified by querying the hospital tumor registry and allocated to the screened cohort if they had undergone any liver imaging within one year prior to HCC diagnosis, while the remainder were allocated to the non-screened cohort. Kaplan–Meier methods and log-rank tests were used to compare 3-year survival curves from an index date of HCC diagnosis. Cox proportional hazard models were used to calculate unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The Duffy adjustment was used to address lead-time bias. Results: A total of 158 patients were included (n = 53 screened, n = 105 non-screened). The median overall survival (OS) for the screened cohort was 19.0 months (95% CI:
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma - 3 month(s) ago
Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with hepatocellular carcinoma (HCC) is exceptionally short, suggesting that trial results are not generalizable to all HCC patients. The downsides of sorafenib use—high …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Therapeutic Potential of Ceramide in Cancer Treatment-PDF - 3 month(s) ago
Gentisic Acid, a Quinonoid Aspirin Metabolite in Cancer Prevention and Treatment. New Horizons in Management of Brain Tumors and Systemic
Source: www.boffinaccess.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16ASCO GI Symposium - reasons to attend - 4 month(s) ago
For more information, visit http://www.asco.org/
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16ASCO GI Symposium - reasons to attend - 4 month(s) ago
For more information, visit http://www.asco.org/
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
PURPOSE Systemic therapy with atezolizumab and bevacizumab can extend life for patients with advanced hepatocellular carcinoma (HCC). However, there is substantial variability in response to therapy and overall survival. Although current prognostic models have been validated in HCC, they primarily consider covariates that may be reflective of the severity of the underlying liver disease of patients with HCC. We developed and internally validated a classification and regression tree (CART) to identify patient characteristics associated with risks of early mortality, at or before 6 months from treatment initiation. METHODS This retrospective cohort study used the nationwide Flatiron Health electronic health record–derived deidentified database and included patients with a diagnosis of HCC after January 1, 2020, who received initial systemic therapy with atezolizumab and bevacizumab. CART was developed from available baseline clinical and demographic information to predict mortality withi
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Interview with @VJOncology regarding our abstract at GI25 https://t.co/Umias7QQHv